Concepedia

De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial

Xiuchun Chen, Dechuang Jiao, Jianghua Qiao, Chengzheng Wang, Xianfu Sun, Zhen-Duo Lu, Lianfang Li, Chong-Jian Zhang, Min Yan, Ya Wei,

The Lancet Oncology · 2024 · 33 citations · 23 references

DOI

Concepts

References

23

Cancer statistics, 2020

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2020 · 21.4K citations · Full text

, , +16

Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer

Dennis J. Slamon, William Godolphin, Lovell A. Jones et al. · Science · 1989 · 6.9K citations

, , +15

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Gϋnter von Minckwitz, Marion Procter, Evandro de Azambuja et al. · New England Journal of Medicine · 2017 · 1.4K citations · Full text

, , +17

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Luca Gianni, W. Eiermann, Alexey Manikhas et al. · The Lancet · 2010 · 1.3K citations

, , +16

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

Gϋnter von Minckwitz, Andreas Schneeweiß, Sibylle Loibl et al. · The Lancet Oncology · 2014 · 1K citations

, , +12